Supernus Pharmaceuticals has received the final approval from the US Food and Drug Administration (FDA) for its supplemental new drug applications (sNDAs) requesting a label expansion for Trokendi XR.

The label expansion for Trokendi XR is to include prophylaxis of migraine headache in adults and adolescents aged 12 and older.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In August last year, Supernus secured tentative approval for one of the two sNDAs.

The Topiramate drug is used to treat migraine prophylaxis and is the most prescribed drug with more than nine million prescriptions a year, representing about 50% of all IMS prescriptions written for migraine prophylaxis.

Supernus Pharmaceuticals president and CEO Jack Khattar said: "This approval and our imminent launch in migraine represent an opportunity for Supernus to further strengthen its leadership position in this market with Trokendi XR.

See Also:

"This approval and our imminent launch in migraine represent an opportunity for Supernus to further strengthen its leadership position in this market with Trokendi XR."

“Trokendi XR, with its novel formulation, provides full 24-hour coverage for patients with smooth pharmacokinetics compared to the immediate-release topiramate products, making it an important new treatment option for adult and adolescent patients suffering from migraine headache."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The once-daily extended release formulation of topiramate, Trokendi XR, is also used to treat epilepsy.

The drug is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.

Supernus has two marketed products for epilepsy, Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate).

It is also developing several product candidates such as SPN-810 for the treatment of impulsive aggression in ADHD patients and SPN-812 for the treatment of ADHD.